Gregory M Heestand, MD
Hematology/Oncology · Templeton
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Heestand’s office at (805) 434-3458 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A92666 · Current
Licensed to practise in California · since 2005 · expires 2027-03-31 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$81,377
Medicare paid this office $81,377 for 196 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 95 | $24,579 | $118 |
| Long return visit (40+ min) | 47 | $17,108 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $12,284 | $106 |
| Long return visit (40+ min) | 35 | $7,648 | $127 |
| New patient visit (60+ min) | 36 | $7,258 | $202 |
See all 11 services
| Return visit (30+ min) | 95 | $24,579 | $118 |
| Long return visit (40+ min) | 47 | $17,108 | $169 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $12,284 | $106 |
| Long return visit (40+ min) | 35 | $7,648 | $127 |
| New patient visit (60+ min) | 36 | $7,258 | $202 |
| Return visit (30+ min) | 24 | $2,842 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,635 | $155 |
| New patient visit (60+ min) | 13 | $2,118 | $163 |
| Short return visit (20+ min) | 16 | $1,524 | $80 |
| Hospital discharge day management, 30 minutes or less | 20 | $1,485 | $74 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $194 | $15 |
Who their Medicare patients are
196 Original Medicare patients in 2024. Average age 74 · Under 65 9% · 85 and older 11% · Women 46% · Also on Medicaid 33% · Health risk score 2.67. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 75% · Diabetes 42% · Cancer 35% · Coronary heart disease 33% · Chronic kidney disease 33% · Atrial fibrillation 23% · Heart failure 17% · Depression 17% · COPD 13% · Dementia 12% · Stroke 11%.
The office billed $395,215, Medicare allowed $104,172 and paid $81,377; for 657 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 196 | 657 | 74 | 2.67 | $395,215 | $81,377 |
| 2023 | 198 | 725 | 74 | 2.66 | $393,088 | $78,481 |
| 2022 | 180 | 620 | 73 | 2.44 | $360,599 | $62,891 |
| 2021 | 176 | 675 | 73 | 2.66 | $375,459 | $68,332 |
| 2020 | 203 | 653 | 72 | 2.51 | $256,143 | $59,397 |
| 2019 | 198 | 583 | 73 | 2.59 | $90,099 | $50,809 |
| 2018 | 212 | 838 | 73 | 2.55 | $135,544 | $75,532 |
| 2017 | 186 | 545 | 73 | 2.28 | $138,600 | $53,829 |
| 2016 | 147 | 618 | 71 | 2.45 | $200,823 | $44,530 |
| 2015 | 165 | 688 | 71 | 2.35 | $226,122 | $52,819 |
| 2014 | 99 | 426 | 71 | 2.41 | $98,766 | $32,645 |
| 2013 | 83 | 390 | 71 | 2.11 | $93,274 | $30,542 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Long return visit (40+ min) | 71 | $24,768 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 49 | $22,081 | $107 |
| Return visit (30+ min) | 97 | $16,915 | $86 |
| New patient visit (60+ min) | 32 | $5,222 | $163 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,532 | $156 |
| Hospital discharge day management, 30 minutes or less | 23 | $1,780 | $74 |
| New patient visit (45+ min) | 12 | $1,319 | $110 |
| Short return visit (20+ min) | 14 | $784 | $56 |
2022: 6 services
| Return visit (30+ min) | 99 | $22,644 | $88 |
| Long return visit (40+ min) | 56 | $17,681 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 36 | $8,973 | $91 |
| New patient visit (45+ min) | 47 | $5,824 | $124 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,958 | $174 |
| Short return visit (20+ min) | 16 | $1,093 | $61 |
2021: 5 services
| Return visit (30+ min) | 103 | $25,734 | $88 |
| Long return visit (40+ min) | 66 | $22,863 | $130 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $6,612 | $94 |
| New patient visit (45+ min) | 44 | $5,690 | $129 |
| Short return visit (20+ min) | 22 | $1,407 | $59 |
2020: 7 services
| Long return visit (40+ min) | 74 | $18,524 | $101 |
| Return visit (30+ min) | 99 | $15,903 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $7,075 | $96 |
| New patient visit (45+ min) | 41 | $4,985 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,843 | $192 |
| New patient visit (60+ min) | 22 | $2,952 | $134 |
| Return visit (30+ min) | 18 | $1,429 | $71 |
2019: 5 services
| Return visit (30+ min) | 104 | $19,281 | $68 |
| Long return visit (40+ min) | 60 | $13,726 | $95 |
| New patient visit (60+ min) | 65 | $9,285 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,019 | $94 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,934 | $161 |
2018: 5 services
| Long return visit (40+ min) | 105 | $28,149 | $96 |
| Return visit (30+ min) | 101 | $22,208 | $69 |
| New patient visit (60+ min) | 85 | $12,283 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $8,051 | $94 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,344 | $122 |
2017: 4 services
| Long return visit (40+ min) | 83 | $19,114 | $99 |
| New patient visit (60+ min) | 107 | $15,581 | $146 |
| Return visit (30+ min) | 69 | $12,203 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $3,833 | $93 |
2016: 6 services
| Long return visit (40+ min) | 66 | $22,432 | $85 |
| Return visit (30+ min) | 98 | $14,206 | $57 |
| New patient visit (60+ min) | 24 | $3,396 | $141 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,444 | $81 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,052 | $42 |
| Short return visit (20+ min) | 18 | $773 | $37 |
2015: 6 services
| Long return visit (40+ min) | 76 | $24,554 | $87 |
| Return visit (30+ min) | 95 | $13,973 | $60 |
| New patient visit (60+ min) | 44 | $5,943 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,720 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,881 | $59 |
| Short return visit (20+ min) | 26 | $1,338 | $36 |
2014: 4 services
| Long return visit (40+ min) | 54 | $17,167 | $86 |
| Return visit (30+ min) | 53 | $8,244 | $58 |
| New patient visit (60+ min) | 35 | $4,412 | $126 |
| Short return visit (20+ min) | 16 | $868 | $36 |
2013: 4 services
| Long return visit (40+ min) | 45 | $16,282 | $84 |
| Return visit (30+ min) | 36 | $5,924 | $60 |
| New patient visit (60+ min) | 37 | $4,631 | $125 |
| Short return visit (20+ min) | 14 | $716 | $38 |
Medicaid work
$13,371 in 2024
Medicaid paid $13,371 for 191 billed services this clinician did in 2024, up to 18 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 102 | $8,287 |
| Return visit (30+ min) | 89 | $5,083 |
| 2024 | 191 | 2 | 18 | $13,371 |
| 2023 | 223 | 2 | 23 | $9,815 |
| 2022 | 204 | 3 | 18 | $5,766 |
| 2021 | 116 | 1 | 17 | $4,295 |
| 2020 | 168 | 2 | 18 | $5,592 |
| 2019 | 225 | 2 | 25 | $8,605 |
| 2018 | 260 | 2 | 19 | $13,538 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 176 | $8,875 |
| Return visit (30+ min) | 47 | $940 |
2022
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 90 | $3,076 |
| Return visit (30+ min) | 84 | $1,751 |
| Long return visit (40+ min) | 30 | $939 |
2021
| Return visit (30+ min) | 116 | $4,295 |
2020
| Return visit (30+ min) | 109 | $3,330 |
| Long return visit (40+ min) | 59 | $2,262 |
2019
| Return visit (30+ min) | 196 | $6,529 |
| Long return visit (40+ min) | 29 | $2,075 |
2018
| Long return visit (40+ min) | 120 | $8,493 |
| Return visit (30+ min) | 140 | $5,045 |
Drugs they prescribed that Part D paid
$36,787
Pharmacies billed $36,787 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 17% of their Part D prescriptions (15 of 91) in 2024. A higher opioid share than 9 in 10 peers; the typical hematology-oncology clinician is at 5%.
76 generic and 15 brand-name prescriptions · $36,787 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Pantoprazole | 13 | $187 | $14 |
| Oxycodone | 14 | $86 | $6 |
Year by year
| 2024 | 91 | 30 | 17% (15) | 16% | $36,787 |
| 2023 | 91 | 39 | None | 30% | $476,350 |
| 2022 | 99 | 37 | None | None | $117,379 |
| 2021 | 140 | 36 | None | 44% | $221,692 |
| 2020 | 166 | 44 | None | None | $151,880 |
| 2019 | 263 | 48 | None | 24% | $224,538 |
| 2018 | 178 | 47 | None | 21% | $174,694 |
| 2017 | 119 | 39 | 9% (11) | 29% | $41,348 |
| 2016 | 258 | 49 | 16% (42) | 36% | $138,084 |
| 2015 | 327 | 64 | 24% (79) | 23% | $130,220 |
| 2014 | 390 | 50 | 30% (118) | 23% | $181,872 |
| 2013 | 309 | 43 | 24% (75) | 22% | $84,790 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Xifaxan | 15 | $36,501 | $2,433 |
2021: 3 drugs
| Xifaxan | 13 | $35,046 | $2,696 |
| Eliquis | 19 | $10,637 | $560 |
| Ursodiol | 15 | $1,498 | $100 |
2020: 4 drugs
| Creon | 15 | $26,972 | $1,798 |
| Clinisol | 27 | $6,011 | $223 |
| Pantoprazole | 23 | $898 | $39 |
| Ondansetron | 14 | $202 | $14 |
2019: 5 drugs
| Clinisol | 52 | $12,131 | $233 |
| Enoxaparin | 19 | $6,402 | $337 |
| Pantoprazole | 42 | $1,424 | $34 |
| Ondansetron | 22 | $305 | $14 |
| Prochlorperazine Maleate | 13 | $151 | $12 |
2018: 4 drugs
| Enoxaparin | 28 | $9,089 | $325 |
| Ondansetron | 18 | $195 | $11 |
| Prochlorperazine Maleate | 22 | $168 | $8 |
| Pantoprazole | 27 | $107 | $4 |
2017: 4 drugs
| Enoxaparin | 12 | $5,502 | $458 |
| Sodium Chloride | 22 | $189 | $9 |
| Ondansetron | 11 | $86 | $8 |
| Prochlorperazine Maleate | 11 | $57 | $5 |
2016: 8 drugs
| Enoxaparin | 24 | $32,572 | $1,357 |
| Creon | 25 | $21,555 | $862 |
| Morphine Sulfate Er | 11 | $550 | $50 |
| Morphine Sulfate | 13 | $254 | $20 |
| Metoprolol | 12 | $143 | $12 |
| Pantoprazole | 15 | $98 | $7 |
| Prochlorperazine Maleate | 12 | $73 | $6 |
| Furosemide | 11 | $43 | $4 |
2015: 9 drugs
| Enoxaparin | 25 | $23,415 | $937 |
| Creon | 12 | $9,000 | $750 |
| Morphine Sulfate Er | 26 | $1,330 | $51 |
| Ondansetron Odt | 11 | $308 | $28 |
| Ondansetron | 21 | $300 | $14 |
| Prochlorperazine Maleate | 34 | $269 | $8 |
| Oxycodone | 16 | $267 | $17 |
| Morphine Sulfate | 15 | $258 | $17 |
| Pantoprazole | 25 | $227 | $9 |
2014: 13 drugs
| Gleevec | 11 | $72,874 | $6,625 |
| Sutent | 13 | $69,160 | $5,320 |
| Oxycontin | 20 | $4,050 | $203 |
| Morphine Sulfate Er | 27 | $1,058 | $39 |
| Ursodiol | 11 | $1,053 | $96 |
| Oxycodone | 28 | $663 | $24 |
| Hydrocodone-Acetaminophen | 20 | $498 | $25 |
| Ondansetron | 22 | $494 | $22 |
| Oxycodone-Acetaminophen | 16 | $443 | $28 |
| Pantoprazole | 36 | $301 | $8 |
| Prochlorperazine Maleate | 36 | $284 | $8 |
| Omeprazole | 21 | $127 | $6 |
| Amlodipine Besylate | 18 | $92 | $5 |
2013: 9 drugs
| Sutent | 12 | $38,535 | $3,211 |
| Oxycodone | 20 | $483 | $24 |
| Morphine Sulfate Er | 15 | $458 | $31 |
| Prochlorperazine Maleate | 34 | $254 | $7 |
| Hydrocodone-Acetaminophen | 17 | $154 | $9 |
| Omeprazole | 12 | $132 | $11 |
| Levothyroxine | 13 | $115 | $9 |
| Ondansetron | 12 | $90 | $7 |
| Lorazepam | 16 | $87 | $5 |
Money from drug and device companies
$303 in 2025
| 2025 | 2 | 2 | None | $303 |
| 2024 | 3 | 3 | $4,390 | $4,408 |
| 2023 | 4 | 12 | $3,915 | $5,594 |
| 2020 | 2 | 5 | $6,460 | $7,075 |
| 2019 | 2 | 15 | $3,880 | $5,502 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Exelixis | Cabometyx | $168 | 1 payment
|
| AstraZeneca UK | None | $135 | 1 payment
|
See all 2 published payments
| AstraZeneca UK | Meals · 2025-01-23 | None | $135 |
| Exelixis | Meals · 2025-01-23 | Cabometyx | $168 |
See earlier years (2024, 2023, 2020, 2019)
2024: $4,408
| AstraZeneca Pharmaceuticals LP | None | $2,740 | 1 payment
|
| Exelixis | Cabometyx | $1,650 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $18 | 1 payment
|
2023: $5,594
| Exelixis | Cabometyx | $3,218 | 7 payments
|
| Eisai | Lenvima | $2,131 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $135 | 1 payment
|
| Genentech USA | None | $111 | 1 payment
|
2020: $7,075
| Exelixis | Cabometyx | $4,455 | 3 payments
|
| Eisai | Lenvima | $2,620 | 2 payments
|
2019: $5,502
| Incyte | None | $5,417 | 14 payments
|
| Exelixis | Cabometyx | $85 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2020 | Their institution | $67,122 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2021 | Their institution | $61,132 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc (Mono Vs Placebo) · 2023 | Their institution | $37,312 |
| E.R. Squibb & Sons, L.L.C. · A Phase 3, Randomized, Double-Blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma After Curative Hepatic Resection Or Ablation · 2025 | Their institution | $15,986 |
| AstraZeneca Pharmaceuticals LP · Medi9447 Cd73 Solid Tmr-D6070c00001 Phase 1 Clinical Trial · 2020 | Their institution | $9,464 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2019 | Their institution | $4,247 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc (Mono Vs Placebo) · 2024 | Their institution | $2,400 |
| E.R. Squibb & Sons, L.L.C. · Phase III Adjuvant Hcc Mono Vs Placebo · 2022 | Their institution | $1,800 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1770568867
- Licence
- CA A92666California A92666: Current · expires 2027-03-31
- Trained
- University of Southern California Keck School of Medicine, 2004
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2005-12-12
- NPI last updated
- 2024-05-07
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 269 Campus Drive, Stanford, CA, 94305